Fax: (011) 82-31-920-1520
Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first†
Result of a randomized pilot study
Article first published online: 5 MAY 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 1, pages 143–149, 1 July 2008
How to Cite
Lee, D. H., Han, J.-Y., Kim, H. T., Yoon, S. J., Pyo, H. R., Cho, K. H., Shin, S.-H., Yoo, H., Lee, S.-H. and Lee, J. S. (2008), Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first. Cancer, 113: 143–149. doi: 10.1002/cncr.23526
Presented in part at the 12th World Conference on Lung Cancer, September 2–6, 2007, Seoul, Korea and at the 14th European Cancer Conference, September 23–27, 2007, Barcelona, Spain.
- Issue published online: 20 JUN 2008
- Article first published online: 5 MAY 2008
- Manuscript Accepted: 11 FEB 2008
- Manuscript Revised: 13 JAN 2008
- Manuscript Received: 31 OCT 2007
- National Cancer Center. Grant Numbers: NCC-0210140, 0510140
- primary chemotherapy;
- whole brain radiotherapy;
- nonsmall cell lung cancer;
- brain metastasis
This randomized pilot trial investigated whether primary chemotherapy was feasible in terms of efficacy, survival, toxicity profile, and quality of life compared with whole-brain radiotherapy (WBRT) given first in chemotherapy-naive patients nonsmall cell lung cancer (NSCLC) with synchronous brain metastasis when neurologic symptoms or signs are absent or controlled by supportive care.
After stratification by Eastern Cooperative Oncology Group performance status (ECOG PS) (0–1 vs 2), the number of intracranial metastases (<3 vs 3≤), and the presence of extrathoracic extracranial metastasis, eligible patients were randomized to the primary chemotherapy arm or the WBRT-first arm. World Health Organization (WHO) response criteria, National Cancer Institute Common Toxicity Criteria (NCI-CTC; version 2.0), and the European Organization for Research and Treatment of Cancer (EORTC) C-30/LC-13 questionnaire were used.
A total of 48 patients were enrolled between August 2002 and November 2005. The response rate of chemotherapy and survival outcomes in the primary chemotherapy arm were not statistically different from those in the WBRT-first arm (overall response rate, 28.0% vs 39.1%; progression-free survival, 3.6 months vs 4.4 months; overall survival, 9.1 months vs 9.9 months). There was close correlation noted between intracranial and extracranial tumor responses (k = 0.82). However, in the WBRT-first arm, grade 3 of 4 neutropenia was more frequent (79% vs 40%) during chemotherapy and 4 patients (17.4%) did not receive further chemotherapy because of early death or poor performance after WBRT. Cognitive function appeared to deteriorate during primary chemotherapy, but was also found to deteriorate after WBRT.
Primary chemotherapy is more feasible and can be an appropriate option for patients with synchronous brain metastasis when neurologic symptoms or signs are absent or controlled. The role and timing of WBRT should be defined in further studies in this clinical setting. Cancer 2008. © 2008 American Cancer Society.